SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch
16 May 2024 - 3:45PM
Business Wire
A revolutionary at-home 12-lead ECG service with 24/7
cardiologist review and telehealth service now fully available in
the US.
SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL"
or the "Company"), a leading provider and developer of
advanced personal telemedicine solutions, is thrilled to announce
that it recently officially launched it’s SmartHeart® membership
program in the US.
This announcement comes after the highly successful soft launch
that was announced in November 2023, which exceeded the company's
expectations, demonstrating substantial demand and positive
customer feedback.
Erez Nachtomy, CEO of SHL Telemedicine commented: "The official
launch marks a significant milestone in our mission to transform
cardiac care accessibility. The overwhelming success of our soft
launch has not only validated the demand for accessible, at-home
cardiac care but also underscored the effectiveness of our
solutions in enhancing heart health management."
This official launch is further bolstered by the recent,
positive results from a clinical study conducted with Imperial
College London, which demonstrated significant reductions in
hospital readmissions and emergency department visits among
post-ACS patients using the SmartHeart® system, underlining its
effectiveness and transformative potential in remote cardiac
care.
Jason Bottiglieri, General Manager of SHL Telemedicine USA
added: “This launch marks a pivotal moment for healthcare
accessibility in the U.S. The SmartHeart® membership brings medical
expertise directly into our customers' homes, enhancing their
ability to manage heart health proactively. Our technology and
service are not just about responding to symptoms but empowering
users to take control of their cardiac health with unprecedented
ease and confidence.”
The SmartHeart® membership is a private pay program designed to
revolutionize home-based access to cardiac care. It includes the
innovative, user-friendly SmartHeart® portable 12-lead ECG device,
offering round-the-clock interpretation by board-certified
cardiologists and on-demand telehealth visits. This initiative not
only simplifies the process of conducting a full 12-lead ECG at
home but also ensures convenient and dependable heart health
management, meeting the evolving needs of today's healthcare
consumers.
SmartHeart® Membership Offers:
- Portable 12-lead ECG Device: The SmartHeart® ECG, a
cutting-edge and user-friendly device, enables high-quality 12-lead
ECG performance anytime and anywhere.
- 24/7 Cardiologist Interpretation: Subscribers have access to
expert analysis of their ECG by board-certified cardiologists,
offering peace of mind and prompt response to cardiac
symptoms.
- On-demand Telehealth Visits: Subscribers can easily access
medical professionals for consultations, enabling timely and
informed health decisions.
For detailed information on subscription options and
availability of the SmartHeart® Membership program in different
states, as well as customer testimonials, please visit our website
at www.getsmartheart.com.
About SHL Telemedicine
SHL Telemedicine is engaged in developing and marketing personal
telemedicine systems and the provision of medical call center
services, with a focus on cardiovascular and related diseases, to
end users and to the healthcare community. SHL Telemedicine offers
its services and personal telemedicine devices to subscribers
utilizing telephonic and Internet communication technology. SHL is
listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885,
Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT,
ISIN: US78423T2006, CUSIP: 78423T200).
For more information, please visit our website at
www.shl-telemedicine.com.
Forward-Looking Statements
Some of the information contained in this press release contains
forward-looking statements. Readers are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those in the forward-looking statements as a
result of various factors. SHL Telemedicine undertakes no
obligation to publicly update or revise any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240515833949/en/
Fabienne Farner, IRF, Phone: +41 43 244 81 42,
farner@irf-reputation.ch
SHL Telemedicine (NASDAQ:SHLT)
Historical Stock Chart
From Oct 2024 to Nov 2024
SHL Telemedicine (NASDAQ:SHLT)
Historical Stock Chart
From Nov 2023 to Nov 2024